Skip to main content
. 2022 Mar 15;14:17588359221083956. doi: 10.1177/17588359221083956

Figure 2.

Figure 2.

AMEERA-5 study design. Randomization will be stratified by de novo metastatic disease (yes or no), menopausal status (yes or no), and visceral metastasis defined by at least one of the following: liver, lung, or brain metastasis or pleural or peritoneal involvement (yes or no).

PO, oral; QD, once daily; SQ, subcutaneous.

aArchived tissue or fresh sample obtained between screening and cycle 1 day 1.

bPre-/perimenopausal women and men will receive a subcutaneous goserelin implant (3.6 mg) on day 1 of every 28-day cycle.